Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diridavumab
- Development stage
- Phase 2
- Lead developer
- Janssen Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Diridavumab is a fully human monoclonal antibody that targets the hemagglutinin (HA) stalk region of influenza A virus. By binding to the HA stalk domain, diridavumab stabilizes the prefusion structure of HA and prevents pH-dependent fusion between viral and cellular membranes in endosomes. This mechanism inhibits viral entry into host cells and blocks infection. Diridavumab was developed for the treatment and prevention of influenza A infections. The drug was originally discovered by Crucell (a Dutch biopharmaceutical company) in collaboration with The Scripps Research Institute and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson (now Johnson & Johnson Innovative Medicine). Clinical development reached phase 2 trials for influenza A virus H1N1 subtype but has since been discontinued[3][4][5][7].
- Other names
- diridavumabCR6261CR-6261CR 6261JNJ-54235025JNJ54235025JNJ 54235025monoclonal antibody CR6261
02
Targets
HA stem (Influenza A hemagglutinin stem region)
Beyond the preview
Go deeper on diridavumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diridavumab.